Moving osimertinib to first-line: the right "strategy" in the chessboard of epidermal growth factor receptor-mutated non-small cell lung cancer? Other Scholarly Work

cited authors

  • Passiglia, Francesco; Raez, Luis E; Rolfo, Christian

sustainable development goals

authors

publication date

  • April 1, 2018

published in

keywords

  • AFATINIB
  • CHEMOTHERAPY
  • ERLOTINIB
  • GEFITINIB
  • Life Sciences & Biomedicine
  • MULTICENTER
  • MUTATIONS
  • NSCLC
  • OPEN-LABEL
  • PHASE-III
  • Respiratory System
  • SURVIVAL
  • Science & Technology

WoS ID

  • 000431688000029

Digital Object Identifier (DOI)

start page

  • S1076

end page

  • S1080

volume

  • 10

international collaboration

  • true

open access

  • true